Menopausal hormone treatment cardiovascular disease: another look at an unresolved conundrum
- 1 April 2014
- journal article
- review article
- Published by Elsevier in Fertility and Sterility
- Vol. 101 (4), 887-897
- https://doi.org/10.1016/j.fertnstert.2014.02.042
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatmentEuropean Heart Journal, 2013
- Timing and Duration of Menopausal Hormone Treatment May Affect Cardiovascular OutcomesAmerican Journal Of Medicine, 2011
- Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failureEuropean Heart Journal, 2008
- Inflammatory Markers and the Risk of Coronary Heart Disease in Men and WomenNew England Journal of Medicine, 2004
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Estrogen and Progestin Compared with Simvastatin for Hypercholesterolemia in Postmenopausal WomenNew England Journal of Medicine, 1997
- Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular DiseaseNew England Journal of Medicine, 1996
- A Prospective Study of Postmenopausal Estrogen Therapy and Coronary Heart DiseaseNew England Journal of Medicine, 1985
- Postmenopausal Estrogen Use, Cigarette Smoking, and Cardiovascular Morbidity in Women over 50New England Journal of Medicine, 1985